Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.19 AUD
Change Today -0.06 / -24.00%
Volume 2.0M
PBT On Other Exchanges
As of 2:10 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

prana biotechnology ltd (PBT) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/5/14 - A$0.36
52 Week Low
02/25/15 - A$0.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

prana biotechnology ltd (PBT) Related Businessweek News

View More BusinessWeek News

prana biotechnology ltd (PBT) Details

Prana Biotechnology Limited develops therapies for the treatment of neurodegenerative diseases in Australia. The company focuses on the Alzheimer‘s and Huntington‘s diseases, as well as other age-related degeneration disorders. Its lead drug candidate includes PBT2 for the treatment of Alzheimer’s and Huntington’s diseases. The company’s other development products that are in pre-clinical trials comprise PBT434 that is used for the treatment of Parkinson’s disease and other movement disorders; and PBT519, which is used to treat brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds, which support new therapies for the treatment of neurodegenerative disease and other highly prevalent conditions. The company was founded in 1997 and is based in Parkville, Australia.

12 Employees
Last Reported Date: 11/3/14
Founded in 1997

prana biotechnology ltd (PBT) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: A$444.4K
Chief Operating Officer
Total Annual Compensation: A$324.8K
Company Secretary
Total Annual Compensation: A$50.0K
Compensation as of Fiscal Year 2014.

prana biotechnology ltd (PBT) Key Developments

Prana Biotechnology Limited Announces the European Commission Approves the Orphan Designation for PBT2 for the Treatment of Huntington's Disease

Prana Biotechnology Limited announced that the European Commission has approved orphan designation for PBT2 for the treatment of Huntington's disease, stating that Prana has shown that PBT2 might be of significant benefit for patients with Huntington's disease. The approval was based on the recommendation of a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The COMP assessed the scientific documentation for PBT2 against the key criteria for orphan designation. The criteria require that PBT2 be intended for the treatment, prevention or diagnosis of a disease that is life-threatening or chronically debilitating; have a prevalence in the EU not more than five in 10,000, and no satisfactory method of diagnosis, prevention or treatment of the condition concerned, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. Orphan designation provides for ten years of market exclusivity in the European Union (EU) from the granting of a marketing authorization (approval for sale). Other benefits relate to assistance in developing clinical protocols, reduced fees, and access to EU-funded research grants.

Prana Biotechnology Limited Reports Consolidated Cash Flow Results for the Third Quarter and Nine Months Ended March 31, 2015

Prana Biotechnology Limited reported consolidated cash flow results for the third quarter and nine months ended March 31, 2015. For the quarter, the company reported net operating cash flows (carried forward) of AUD 4,360,000 and payment for acquisition of physical non-current assets of AUD 4,000. For the nine months, the company reported net operating cash flows (carried forward) of AUD 12,783,000 and payment for acquisition of physical non-current assets of AUD 26,000.

Prana Biotechnology Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Prana Biotechnology Limited reported consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported loss after income tax of AUD 1,252,695 compared to AUD 7,928,392 for the same period a year ago. Revenue from ordinary activities was AUD 92,581 compared to AUD 189,588 a year ago. Loss before income tax expense was AUD 1,252,695 compared to AUD 7,928,392 a year ago. Basic and diluted loss per share was 0.26 cents compared to 1.97 cents a year ago. Net operating cash flows were AUD 8,411,407 compared to AUD 7,435,475 a year ago. Payment for purchases of plant and equipment was AUD 24,942 compared to AUD 12,718 a year ago. The loss has decreased compared to previous year due to a gain on foreign exchange, an increase in other income related to the R&D Tax Concession and a decrease in expenditure on research and development.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBT:AU A$0.19 AUD -0.06

PBT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBT.
View Industry Companies

Industry Analysis


Industry Average

Valuation PBT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.7x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRANA BIOTECHNOLOGY LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at